The advent of MRI-guided radiation therapy has introduced MRI’s powerful soft- tissue contrast into the treatment room, offering strong potential for improved targeting in many disease sites. In February 2017, ViewRay’s MRIdian linear accelerator (linac) received FDA clearance and the first patient treatment using MRIdian® Linac was conducted at Henry Ford Cancer Institute in July 2017. In this webinar, two key physicists involved in this project, Anthony Doemer, M.S., and Carri Glide-Hurst, Ph.D., will present their commissioning and clinical experience. Initial site planning, shielding, and MR safety considerations will be shared. The design aspects and functionality of the double-focused MLC, mechanical, and radiation characterization and validation will be presented. Commissioning of the MRI system, including novel aspects such as distortion assessment and field homogeneity in the presence of the linear accelerator will be highlighted. First clinical images and treatment plans will be shared to highlight the first months of clinical operation.